Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Scholarly Papers

1-1-2014

Phenotype of Transgenic Mice Carrying a Very
Low Copy Number of the Mutant Human G93A
Superoxide Dismutase-1 Gene Associated with
Amyotrophic Lateral Sclerosis
Jeffrey S. Deitch
Guillermo M. Alexander
Andrew Bensinger
Philadelphia College of Osteopathic Medicine, andrewben@pcom.edu

Steven Yang
Philadelphia College of Osteopathic Medicine, stevenya@pcom.edu

Juliann T. Jiang
See next page for additional authors

Follow this and additional works at: http://digitalcommons.pcom.edu/scholarly_papers
Part of the Nervous System Diseases Commons
Recommended Citation
Deitch, Jeffrey S.; Alexander, Guillermo M.; Bensinger, Andrew; Yang, Steven; Jiang, Juliann T.; and Heiman-Patterson, Terry D.,
"Phenotype of Transgenic Mice Carrying a Very Low Copy Number of the Mutant Human G93A Superoxide Dismutase-1 Gene
Associated with Amyotrophic Lateral Sclerosis" (2014). PCOM Scholarly Papers. Paper 229.
http://digitalcommons.pcom.edu/scholarly_papers/229

This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by
an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Authors

Jeffrey S. Deitch, Guillermo M. Alexander, Andrew Bensinger, Steven Yang, Juliann T. Jiang, and Terry D.
Heiman-Patterson

This article is available at DigitalCommons@PCOM: http://digitalcommons.pcom.edu/scholarly_papers/229

Phenotype of Transgenic Mice Carrying a Very Low Copy
Number of the Mutant Human G93A Superoxide
Dismutase-1 Gene Associated with Amyotrophic Lateral
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Terry D. Heiman-Patterson1*
1 Department of Neurology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America, 2 Philadelphia College of Osteopathic Medicine,
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Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor neuron. While most cases of ALS
are sporadic, 10% are familial (FALS) with 20% of FALS caused by a mutation in the gene that codes for the enzyme Cu/Zn
superoxide dismutase (SOD1). There is variability in sporadic ALS as well as FALS where even within the same family some
siblings with the same mutation do not manifest disease. A transgenic (Tg) mouse model of FALS containing 25 copies of
the mutant human SOD1 gene demonstrates motor neuron pathology and progressive weakness similar to ALS patients,
leading to death at approximately 130 days. The onset of symptoms and survival of these transgenic mice are directly
related to the number of copies of the mutant gene. We report the phenotype of a very low expressing (VLE) G93A SOD1 Tg
carrying only 4 copies of the mutant G93ASOD1 gene. While weakness can start at 9 months, only 74% of mice 18 months
or older demonstrate disease. The VLE mice show decreased motor neurons compared to wild-type mice as well as
increased cytoplasmic translocation of TDP-43. In contrast to the standard G93A SOD1 Tg mouse which always develops
motor weakness leading to death, not all VLE animals manifested clinical disease or shortened life span. In fact,
approximately 20% of mice older than 24 months had no motor symptoms and only 18% of VLE mice older than 22 months
reached end stage. Given the variable penetrance of clinical phenotype, prolonged survival, and protracted loss of motor
neurons the VLE mouse provides a new tool that closely mimics human ALS. This tool will allow the study of pathologic
events over time as well as the study of genetic and environmental modifiers that may not be causative, but can exacerbate
or accelerate motor neuron disease.
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FALS patients, possessing the same SOD1 mutation, do not show
signs of the disease [4]. The role that SOD1 plays in the
pathogenesis of ALS is not currently understood. The large
variation in age of onset and severity in human ALS patients with
specific SOD1 mutations lends support to the likelihood that there
are other variables that determine disease expression. These
variables likely include both environmental and genetic modifiers
of disease [5,6].
Transgenic (Tg) mouse models of FALS containing mutant
human SOD1 genes have led to an explosion of research into the
causes of ALS [7–9]. The most utilized and best characterized Tg
mice are the G93A mutant hSOD1 [Tg(hSOD1-G93A)1GUR],
abbreviated G93A, which develop motor neuron pathology and
clinical symptoms remarkably similar to those seen in ALS patients
[9–12]. These mice show onset with weakness of the hind limbs
and tremors at approximately 90 days of age followed by hind

Introduction
Amyotrophic lateral sclerosis (ALS) is a degenerative disease
affecting primarily the motor neurons in the spinal cord,
brainstem, and motor cortex. Degeneration of the motor neurons
leads to progressive paralysis, atrophy of denervated muscles, and
ultimately death, with a median survival of less than 5 years.
However, there is variability in ALS severity, with 20% of patients
living longer than 5 years and 10% of patients living 10 years or
more. Although most cases of ALS are sporadic (SALS), about 5–
10% of ALS cases are familial (FALS), with approximately 20% of
these resulting from mutations in the ubiquitously expressed Cu/
Zn superoxide dismutase (SOD1) gene [1,2]. Currently, 177 ALS
causing mutations have been identified in the human SOD1 gene.
There is significant heterogeneity of the disease reported in FALS
subjects with SOD1 mutations [3]. Paradoxically, some siblings of
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limb paralysis and death by 120–150 days of age. The timing of
symptoms is directly dependent on the number of copies of the
transgene [11,13].
The standard G93A mutant hSOD1 mouse model carries 25
copies of the mutant human SOD1 gene [14]. Loss of transgene
copies can occur spontaneously during reproduction as a result of
intra-locus recombination during meiosis. Our lab has developed a
unique colony of G93A SOD1 mice that have only 4 copies of the
G93ASOD1 gene with prolonged survival. These mice, designated
as very low expressing (VLE) G93A SOD1 Tg, have a variable
phenotype and do not always manifest clinical phenotype. Since
the VLE mouse has a less penetrant phenotype with slower
progression, it provides a model to study pathologic changes in
sequence over a longer period of time so that the pathogenetic
mechanisms can more easily be dissected. In addition, it also
provides a model to study gene-environment interactions in
disease expression as proposed in both familial and sporadic ALS
[15]. The aim of this study is to characterize the clinical and
pathologic phenotype of the VLE G93A SOD1 Tg mouse model
of ALS which, like humans, has a variable penetrance.

citrate buffer (pH 6.0) for 40 min in a vacuum oven. After a 30min cooling period, the sections were rinsed, incubated in
methanol/3% H2O2 for 20 min to quench endogenous peroxidase, and blocked with 0.1% bovine serum albumin (BSA) with
5% normal goat serum. Primary antibodies against TARDBP/
TDP-43 (Proteintech, Chicago, IL; 1:500) were added and the
sections incubated over night at room temperature in a humidifier
chamber. After rinsing, sections were incubated with biotinylated
anti-rabbit secondary antibodies for 1 h, rinsed, and then
incubated with avidin–biotin–peroxidase complex. Sections were
developed with a diaminobenzidine (DAB) substrate and counter
stained with Hematoxylin.
Motor neurons were characterized for the location of TDP-43
staining from 0 (pale cytoplasm with distinct nuclear staining) to 2
(translocation of the TDP-43 staining from the nucleus to the
cytoplasm). The resulting scores were compared by age and
between mutant and control mice and most importantly, the
percent of neurons with translocation of TDP-43 to the cytoplasm
was noted. TDP-43 for each animal was characterized in duplicate
by two independent observers and averaged to limit subjectivity.

Materials and Methods

Ethics
All animal procedures described in this study were carried out in
accordance with and approved by the institutional animal care
and use committee (IACUC) at Drexel University College of
Medicine.

Mice used in this study originated from a colony of C57BI/
6JXSJL/J Fn mice hemizygous for the human G93A SOD1 gene.
The VLE mice were derived from a spontaneously generated
founder male that possessed only 4 copies of the G93ASOD1
gene. Transgene copy number was verified for every animal using
QPCR as previously described [5,13].
Two hundred and twenty three mice, 125 Tg+ VLE and 98 Tgwild type controls, were evaluated for this study. Clinical status of
each mouse was assessed by measuring weight and by ranking the
splay reflex test on a 0–3 scale (Figure 1). Thirty three of these
mice were used for lumbar spinal cord motor neuron counts and
TDP-43 immunohistochemistry. The mice were sacrificed at three
time points, 9, 18, and 24 months of age. If prior to the scheduled
time point the mouse demonstrated paralysis of one hind limb, or
was unable to right itself in 30 seconds when placed on its side, the
animal was sacrificed. Natural death was not an endpoint in this
study. Mice were euthanized by intraperitoneal injection of
Beuthanasia-D (solution of sodium pentobarbital and sodium
phenytoin, Schering, Kenilworth, NJ) at a dose containing
150 mg/kg pentobarbital followed by transcardial perfusion with
4% formaldehyde in 0.1 M phosphate buffered saline (PBS). The
lumbar spinal cord was dissected out, embedded horizontally in
paraffin, sectioned in 10 um-thick sections and mounted on
gelatin-coated slides.
For neuron counts, every third section was stained with 1%
Thionin. The ventral horns of the spinal cord were identified in
relation to the presence of the central spinal canal, and all motor
neurons in Rexed layer 9 of the lumbosacral segments were
counted. All images were collected and analyzed with an Olympus
BX60 microscope equipped with a DP70 digital camera and DP
software (Olympus America, Center Valley, PA, USA). Motor
neurons counts were performed by two independent counters and
averaged to limit subjectivity.
The motor neurons of the spinal cord were also qualitatively
examined for the presence of TDP-43. Immunohistochemistry was
performed using an avidin–biotin–peroxidase complex system
(Vectastain Elite ABC Peroxidase Kit; Vector Laboratories,
Burlingame, CA). Briefly, paraffin was removed by xylene
treatment, and the sections rehydrated through descending grades
of alcohol up to water. Non-enzymatic antigen retrieval was
performed by heating the sections to 95uC in 0.01 M sodium
PLOS ONE | www.plosone.org

Results
Genotyping
All of the VLE mice were positive for human SOD1 by QPCR
with a delta CT versus Interleukin-2 (IL-2) consistent with four
copies of the transgene [13]. Transgene negative litter mates were
used as controls.

Clinical Status
Significant weight loss can be used as an indicator of disease
progression in high copy-number transgenic mice. There were
significant (p,0.05) differences in weight at all ages between male
and female mice (males heavier than females) in both transgene
positive and negative mice, therefore weight loss as an indicator of
motor neuron loss was evaluated separately by gender. Although
female wild-type mice were on average slightly heavier than their
transgenic litter mates, the difference between their weight at any
of the ages examined did not reach statistical significance (p.
0.05). For ages less than 18 months old, there was no statistically
significant difference (p.0.05) in the weight of male transgenic
mice as compared to their wild-type litter mates. However, for
ages greater than 18 months old, the male transgene positive mice
demonstrated significant (p,0.05) weight loss as compared to their
wild-type litter mates (Figure 2).
There was significantly (p,0.05) increased motor weakness
(evaluated with the splay reflex) in the VLE mice as compared to
control animals (Figure 3). The transgenic mice demonstrated
splay scores greater than 1 in 10% of the animals by 9 months. In
mice between 9 and 18 months of age, 20% of animals showed
splay .1 and 74% of mice older than 18 months showed splay .
1. Hind limb paralysis was observed in VLE mice as early as 22
months. However, only 18% of VLE mice older than 22 months
demonstrated hind limb paralysis. The average survival for
animals that developed hind limb paralysis was 625.0660.8 days.
Not all VLE animals manifested clinically evident disease or
shortened life span with approximately 20% of mice older than 24
months not manifesting any symptoms of motor neuron disease.
2
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Figure 1. Splay reflex test. The splay reflex test, scored on a 0–3 scale, is performed by lifting the mouse by its tail and observing the degree of
hind limb splay.
doi:10.1371/journal.pone.0099879.g001

decrease in the number of lumbosacral spinal cord motor neurons
that reached statistical significance (p,0.05) in the 18 and 24
month old mice (Figure 5). Signs of individual degenerating motor
neurons were observed in VLE mice as early as 9 month old with
vacuolation even before significant neuronal loss.

Motor Neurons
The alpha motor neurons, which are the largest cells (.30 mm
diameter) in the spinal cord, are located in Rexed layer 9 and
easily identified (Figure 4). The lumbosacral spinal cord alpha
motor neurons counts for VLE and control mice are illustrated in
Figure 5. The wild-type control mice demonstrated a stable
number of motor neurons (27696214, mean 6 se) with no
statistically significant difference in numbers (p.0.05) between the
9, 18 and 24 month old animals (p.0.05). In contrast, as
compared to controls, the VLE mice showed a progressive

TDP-43 Immunohistochemistry
The distribution of TDP-43 immunoreactivity in spinal cord
motor neurons is illustrated in Figure 6. In young animals, most
TDP-43 is located in the nucleus with light cytoplasmic staining
(Figure 6A). As the animals aged, the nuclear staining decreased
and there was an increase in cytoplasmic staining (Figure 6B and

Figure 2. Variation in weight with age in male mice. Weight
(mean 6 standard error) of male VLE mice and control litter mates in
four age groups. At ages less than 18 months old, there was no
statistically significant difference (p.0.05) in the weight of male control
mice as compared to the VLE animals. However, for ages greater than
18 months old, the male VLE mice demonstrated significant (p,0.05)
weight loss as compared to their wild-type litter mates.
doi:10.1371/journal.pone.0099879.g002

PLOS ONE | www.plosone.org

Figure 3. Variation in splay score with age. Splay score (mean 6
standard error) of VLE mice and control litter mates in four age groups.
The VLE mice demonstrated significant (p,0.05) greater splay scores as
compared to their wild-type litter mates at all age groups.
doi:10.1371/journal.pone.0099879.g003
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Figure 4. Lumbar spinal cord thionin stain. Lumbar mouse spinal
cord 8 mm paraffin sections stained with thionin. [A] Transverse section.
[B] Horizontal spinal cord section through the lumbar anterior horn at a
level approximates by the arrows in [A]. [C] Motor neurons in Rexed
layer 9.
doi:10.1371/journal.pone.0099879.g004

6C). This shift in TDP-43 immunoreactivity was more pronounced in the VLE mice as compared to their wild-type litter
mates (Figure 7). In the 9 month old mice (Figure 7A) the percent
of motor neurons in which the staining was nuclear only (score = 0)
was 66.668.72% (mean 6 sd) in control mice and 56.164.95% in
VLE mice. There was partial translocation to the cytoplasm in
29.567.43% of the motor neurons in the control mice vs.
37.463.71% in VLE mice. TDP-43 was translocated to the
cytoplasm in 3.8261.69% of control motor neurons vs.
6.4861.76% in VLE mice. This was a statistically significant
difference (p = 0.0321).
In the 18 month old mice (Figure 7B), the percent of motor
neurons with only nuclear staining (score = 0) in control mice was
67.264.62% compared to 53.065.33% in VLE. Partial translocation (score = 1) was observed in 28.963.66% of the motor
neurons in the control mice compared to 36.563.98% in VLE
mice. Cytoplasmic translocation (score = 2) was observed in
3.7761.94% of the motor neurons in the control mice compared
with 10.6863.35% in VLE mice. These differences were all
statistically significant (p,0.01).
In the 24 month old mice (Figure 7C), the percent of motor
neurons with only nuclear staining (score = 0) in control mice was
60.064.62% compared to only 51.065.64% in VLE mice. There
was partial translocation of TDP 43 to the cytoplasm in
33.760.77% of the motor neurons in the control mice compared
to 36.162.98% in VLE mice. Cytoplasmic translocation
(score = 2) was observed in 6.1563.81% of the motor neurons in
control mice compared to 12.8463.61% in VLE mice. These
differences were statistically significant (p,0.05) for nuclear
localization and cytoplasmic translocation. In contrast to control
mice, there was a consistent trend to cytoplasmic localization of
TDP-43 in the VLE animals at each age and the cytoplasmic
translocation of TDP-43 increased over time (Figure 7D).

Figure 5. Variation in lumbosacral motor neuron numbers with
age. Motor neuron numbers in the lumbosacral spinal cord a
progressive reduction over time in the VLE mice as compared to the
control animals. The decrease in motor neurons reached statistical
significance in the 18 and 24 months old mice.
doi:10.1371/journal.pone.0099879.g005

G93ASOD1 mice [13]. In contrast to the VLE mice, these mice
did not demonstrate variable penetrance. The variable penetrance
despite neuronal loss and translocation of TDP 43 support the
VLE model as an important tool to dissect pathologic changes
over time and to examine the interaction of environmental and
genetic factors in ALS onset and progression.
VLE mice demonstrate motor neuron loss at a slower rate with
a protracted time course as compared to the 25 copy G93ASOD1
animals. At 9 months of age, even before significant motor neuron
loss, there was vacuolation of the motor neurons observed similar
to 25 copy G93ASOD1 mice at 30 days of age. Two year old VLE
mice lost approximately 50% of their motor neurons; a loss
comparable to a 70 day old 25 copy G93ASOD1 mouse. By two
years of age 80% of the VLE mice had clinically evident disease
with about one fifth of these animals at end stage. The remaining
animals did not manifest any clinical signs of disease. The average
survival of mice demonstrating paralysis was 625 days compared
with 129 days in the 25 copy mouse. Thus there is clearly a slower
time course of neuronal loss and a clinically variable phenotype in
the VLE mice as compared to the 25 copy G93ASOD1 animals.
In contrast to other G93A SOD1 mutant mouse models which
develop an ALS phenotype that eventually leads to hind limb
paralysis and death, not all VLE animals manifested clinically
evident disease or shortened life span. Only 18% of VLE mice
older than 22 months demonstrated hind limb paralysis with
approximately 20% of mice older than 24 months not manifesting
any symptoms of motor neuron disease.
This slow progression of disease is likely to be more reflective of
human SOD1 mediated ALS and will allow the sequential study of
pathologic changes much more easily than the rapid course of the
25 copy mouse. In fact, it has previously been noted that
translocation of TDP-43 was not a prominent feature of the G93A
SOD1 transgenic mouse model carrying 25 copies of the
transgene. However, the slow progression and prolonged survival
of the VLE mouse allowed us to observe significant translocation
of TDP-43 into the cytoplasm from the nucleus. This would

Discussion
We have demonstrated that VLE mice carrying 4 copies of the
mutant human G93A SOD1 gene on the mixed B6/SJL
background have clinical motor and pathologic changes with
neuronal loss and translocation of TDP-43 when compared to
controls yet, not all of these animals demonstrate weakness or die
at an earlier age. While a previous report described a prolonged
survival in a B6 G93A SOD1 mouse colony with reduced copy
numbers, these mice all showed onset at 12 months with survival
to 15 months [16], suggesting a copy number of less than 8 and
greater than 4 based on our previously published work in B6SJL
PLOS ONE | www.plosone.org
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Figure 6. Lumbar spinal cord TDP-43 Immunohistochemistry. Characterization of TDP-43 staining in a 673 day old VLE mouse. [A] Motor
neuron with normal TDP-43 distribution: a darkly stained nucleus and an even, lightly stained cytoplasm graded as a zero. [B] Demonstrates mixed
localization with redistribution of TDP-43 into diffuse cytoplasmic staining with reduced label in the nucleus and is graded as a one. [C] Demonstrates
motor neuron with redistribution of TDP-43 into punctate staining in the cytoplasm and nucleus and is scored as a two.
doi:10.1371/journal.pone.0099879.g006

further support the VLE mouse as a more realistic model of
human disease than the 25 copy G93ASOD1 mouse.

Finally, similar to FALS kindred’s, not all VLE animals that
carry the four copies of the transgene manifested clinically evident

Figure 7. Translocation of TDP-43 with Age. Localization of TDP-43 in motor neurons of VLE and control mice sacrificed at 9, 18 and 24 months
old (A, B, C). At each age there is an increase in the amount of motor neurons that demonstrate translocation of TDP-43 out of the nucleus into the
cytoplasm in the VLE mice as compared to the control animals. These differences are statistically significant at each age at p,0.05. When only the VLE
is shown over time (D) the increased percentage of motor neurons demonstrating translocation of TDP-43 is evident.
doi:10.1371/journal.pone.0099879.g007
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disease or shortened life span. In fact approximately 20% of these
animals did not manifest any symptoms of motor neuron disease.
This characteristic underscores the increased similarity of this
model to human disease and will enable investigators to more
easily study environmental and genetic factors that can provoke
disease or alter phenotype by using this model. Simply, a
comparison of the percentage of animals clinically affected, the
timing of disease onset, and survival between groups of VLE mice
who are exposed versus not exposed to a particular environmental
factor will provide insight into the gene-environment interaction.
We recognize that variable phenotype could result from
differential expression of mutant SOD1 by the VLE mice.
However, we have previously reported on phenotype variability
in transgenic mouse models of ALS [17]. Our study showed that in
mice expressing the same number of G93A SOD1 transgene
copies, the phenotype variability is mostly due to genetic
background variability and not SOD1 expression. The authors
feel that given the mixed genetic background (C57BL6/SJL) of the
VLE mice most of the variability in ALS phenotype is likely due to
genetic background variations and not differential expression of
SOD1.
While we acknowledge that the slow progression and variable
disease penetrance of the VLE model may demand longer time
periods of study, we feel that using these animals in the
appropriate way can actually accelerate our understanding of

disease. In fact these animals would provide and ideal model to
more easily study environmental and genetic factors that can
provoke disease or alter phenotype. One example would be to
examine the effects of pro-oxidant environmental risk factors and
the genetic predisposition to the generation of free radicals in the
VLE animals to determine the effects of exposure on the
percentage of animals developing disease, the onset, the severity
and the lifespan of affected animals. Furthermore, the slow tempo
of neuronal loss and changes would enable a clearer picture of
sequential events in the progression of motor neuron loss and the
accompanying pathologic changes in spinal microglia and
astrocytes.
In summary, we describe a new tool in the study of SOD1
mediated disease, the VLE mouse model with a variable
penetrance of clinical phenotype, prolonged survival and protracted pathologic loss of motor neurons. These characteristics
make the VLE mouse a valuable model for the study of genetic
and environmental modifiers that may not be causative, but can
exacerbate or accelerate motor neuron disease.
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